News - OBI Pharma 台灣浩鼎

2016.Jul.27

未分類

Corporate

Quick Takes on Promising New Approaches to Treating Breast Cancer

2016.Jul.26

未分類

Corporate

ASCO KOL interviews: Dr. Hope Rugo／Dr. James C. Paulson

2016.Jun.05

未分類

Corporate

OBI Pharma Presents Data for Novel Investigational OBI-822/OBI-821 in Patients with Metastatic Breast Cancer at the 2016 American Society of Clinical Oncology Annual Meeting

2016.May.19

未分類

Corporate

OBI’s Abstract at ASCO 2016: Randomized Phase 2/3 Trial of Active Immunotherapy With OPT-822/OPT-821 in Patients With Metastatic Breast Cancer

2016.May.19

未分類

Corporate

OBI Pharma to Present New Data at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

2016.May.13

未分類

Corporate

Company Position Statement Regarding Recent Investigation of Senior Executives

2016.Mar.31

未分類

Corporate

OBI Pharma Announces Decision By ASCO to Accept its Abstract for Oral Presentation at ASCO’S 2016 Annual Meeting

2016.Feb.21

未分類

Corporate

OBI Pharma Reports Topline Results from OBI-822/821 Randomized Controlled Phase 2/3 Clinical Trial in Patients with Metastatic Breast Cancer

2015.Oct.05

未分類

Corporate

OBI Pharma Enters Exclusive Agreement with MSD for Rights to DIFICID® (fidaxomicin) in Taiwan

2015.Aug.31

未分類

Corporate

OBI Pharma to Unblind its Phase 2/3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer by March 2016

Announcements

Latest announcements

Events

Latest events